C-CEO Formulation for Osteoarthritis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis do not effectively slow or arrest the progression of the disease and are often associated with detrimental side effects, while nutraceutical-based compounds lack clear evidence of effectiveness in treating or preventing arthritis.
Innovation Solution
A formulation comprising carvacrol, curcumin, epigallocatechin-3-gallate, and oligomeric procyanidins, known as the C′-CEO formulation, is administered to treat or prevent arthritis by increasing expression of the chondroprotective molecular target CITED2, suppressing cartilage degradation enzymes, and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If pharmacological agents such as NSAIDs, corticosteroids, or opioids are used to treat osteoarthritis, then pain relief is achieved, but detrimental gastrointestinal, renal, and cardiovascular side effects occur with long-term use
Solution Approach 1:
The patent combines multiple natural compounds (curcumin, boswellic acid, resveratrol, green tea catechins, and other polyphenols) into a composite formulation. This composite approach leverages the synergistic effects of different compounds to achieve effective pain relief and anti-inflammatory action while maintaining safety profiles suitable for long-term use, avoiding the severe side effects associated with conventional pharmacological agents.
2Object-affected harmful factors
If current pharmacological therapies are used to treat osteoarthritis, then some disease symptoms are relieved, but the progression of the disease is not effectively slowed or arrested
Solution Approach 1:
The patent replaces conventional pharmacological mechanisms (NSAIDs, corticosteroids, opioids) with a plant-based polyphenolic formulation that acts through multiple molecular pathways. This formulation targets cartilage degradation enzymes, inflammatory mediators, and oxidative stress pathways simultaneously, providing both symptom relief and disease-modifying effects that slow or arrest osteoarthritis progression.
3Object-generated harmful factors
If nutraceutical-based compounds such as curcumin, glucosamine, or hyaluronic acid are used to treat joint pain and arthritis, then they are marketed as safe alternatives, but their effectiveness in treating or preventing arthritis has not been clearly demonstrated
Solution Approach 1:
The patent merges multiple individually studied nutraceutical compounds (curcumin, boswellic acid, resveratrol, green tea catechins, and other polyphenols) into a single synergistic formulation. This combination approach consolidates the proven safety profiles of natural compounds while achieving demonstrable effectiveness through coordinated action on multiple disease pathways, including inhibition of cartilage degradation and reduction of inflammation.
Data Source
AI summary
Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins.